Sidley represented Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, in its multi-year, multi-target strategic collaboration agreement with Seagen Inc. (Nasdaq: SGEN) to advance a new class of medicines called Degrader-Antibody Conjugates (DACs) for use in cancer treatment. […]
The post Sidley Represents Nurix Therapeutics in Multi-Year Strategic Collaboration With Seagen to Advance New Class of Cancer Therapeutics appeared first on Legal Desire Media and Insights.